The Tg197 mouse model was successfully used in establishing the therapeutic efficacy of Remicade®, the first anti-TNF therapeutic to be successfully applied in the clinic, and is recommended by the FDA for screening potential anti-rheumatoid candidate drugs.
Tg197 is a transgenic mouse overexpressing human TNF resulting in the spontaneous development of arthritis whose pathology closely resembles human rheumatoid arthritis. The mice develop arthritis with 100% penetrance and provide a fast in-vivo model for evaluating human therapeutics targeting rheumatoid arthritis.
